Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy.

Both CAPRA and STAR-CAP prognostic group staging systems provide sufficient stratification and their predictive ability for 5-year BCR-free survival is comparable, with a small advantage for CAPRA (3%).